News by Tag: Us Epo Products
Monoclonal Antibodies (mAbs) to Dominate Protein-Based Therapies Market
April 18, 2012
With products like Avastin, Remicade, Herceptin and Rituxan having blockbuster status almost each year, the mAbs segment holds a tremendous potential in terms of revenue generation, says RNCOS.
April 18, 2012
With products like Avastin, Remicade, Herceptin and Rituxan having blockbuster status almost each year, the mAbs segment holds a tremendous potential in terms of revenue generation, says RNCOS.